Erasmus School of Health Policy & Management
Assistant professor | Health Technology Assessment (HTA)
- thielen@eshpm.eur.nl
- Room
- J8-15
- Location
- Burg. Oudlaan 50, Rotterdam
More information
Work
- R. J.S.D. Heine, F. W. Thielen, R. H.J. Mathijssen, R. W.F. van Leeuwen, M. G. Franken & C. A. Uyl-de Groot (2024) - Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab - PLoS ONE, 19 (2 February) - doi: 10.1371/journal.pone.0293264 - [link]
- Leona Hakkaart - van Roijen, Stijn Peeters, Tim Kanters, Pieter van Baal, Werner Brouwer, Ruben Drost, Silvia M.A.A. Evers, Job van Exel, Vivian Reckers-Droog, Nasr-Eddine Tannaoui, Frederick Thielen & Ben Wijnen (2024) - Kostenhandleiding voor economische evaluaties in de gezondheidszorg:: Methodologie en Referentieprijzen (Herziene versie 2024) - [link]
- Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - European Journal of Haematology, 111 (2), 240-246 - doi: 10.1111/ejh.13987 - [link]
- Lj Bakker, Fw Thielen, Wk Redekop, CA Uyl de Groot & Hm Blommestein (2023) - Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma - BMC Medical Research Methodology, 23 (1) - doi: 10.1186/s12874-023-01952-2 - [link]
- Ngoc Do & Frederick W. Thielen (2023) - Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View - Value in Health, 26 (4), 477-486 - doi: 10.1016/j.jval.2022.11.002 - [link]
- Frederick W. Thielen, Renaud J.S.D. Heine, Sibren van den Berg, Renske M.T.ten Ham & Carin A.Uyl de Groot (2022) - Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma - Cytotherapy, 24 (12), 1245-1258 - doi: 10.1016/j.jcyt.2022.09.002 - [link]
- Frederick W. Thielen, Renaud J.S.D. Heine, Sibren Van Den Berg, Renske M.T. Ten Ham & Carin A. Uyl-De Groot (2022) - Kostprijs-plusmodel geeft inzicht in reële prijzen gentherapieën - Pharmaceutisch Weekblad, 157 (47), 18-20 - [link]
- Frederick W. Thielen, Marie José Kersten, Pim Kuizenga, Mels Hoogendoorn, Eduardus F.M. Posthuma, Wendy B.C. Stevens, Carin A Uyl-de Groot & Hedwig M. Blommestein (2021) - Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view - Expert Review of Anticancer Therapy, 21 (12), 1411-1422 - doi: 10.1080/14737140.2021.1971520 - [link]
- Kai Ruggeri, Julia P. Stuhlreyer, Johanna Emilia Immonen, Silvana Mareva, Maja Friedemann, Alessandro F. Paul, Matthew Lee, Rachel C. Shelton, Annalisa Robbiani, Frederick W. Thielen, Amiran Gelashvili, Filippo Cavassini & Faisal Naru (2021) - Policy evaluation and behavioral economics - doi: 10.4324/9781003181873-11 - [link]
- Renaud Heine, Frederick W. Thielen, Marc Koopmanschap, Marie José Kersten, Hermann Einsele, Ulrich Jaeger, Pieter Sonneveld, Jorge Sierra, Carin Smand & Carin A. Uyl-De Groot (2021) - Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future - HemaSphere, 5 (2) - doi: 10.1097/HS9.0000000000000524 - [link]
- Frederick Thielen (2018) - Best Student Poster Presentation
- WF (Frederick) Thielen (2013) - ESST European Award for Aspiring Undergraduates
Dark Peak Analytics
- Start date approval
- januari 2022
- End date approval
- januari 2025
- Place
- SHEFFIELD
TriData
- Start date approval
- januari 2022
- End date approval
- januari 2025
- Place
- UTRECHT
- Description
- Teacher Statistical Programming & Data Science
EU-HEM Summerschool 2023
- Year
- 2023
- Course Code
- GWSUM2021
Pharmaceutical Pricing and Market Access
- Year Level
- master, master, master, master
- Year
- 2023
- Course Code
- GW4575M
Health Technology Assessment (Eu-HEM)
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4585M
Master Thesis HE
- Year Level
- master, master
- Year
- 2023
- Course Code
- GW4592M
Master HEPL-HE 2023-2024
- Year
- 2023
- Course Code
- GWMTTHEPL
Advanced Health Economic Modelling EuHEM
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4587M
Health Technology Assessment
- Year Level
- master, master, master
- Year
- 2023
- Course Code
- GW4546M
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4555M
Advanced Health Economic Modelling
- Year Level
- master, master, master
- Year
- 2023
- Course Code
- GW4563M
